RNA Technologies & Therapeutics (RNA T&T) Inc.

What RNA Technologies & Therapeutics (RNA T&T) Inc. does

RNA Technologies & Therapeutics (RNA T&T) Inc. is a privately-held Canadian biotechnology company founded in 2022 and headquartered in Montréal. Per its stated short description, the company designs, optimizes, and produces high-quality RNA and offers RNA-based therapeutic development services — positioning it as a contract development / manufacturing-style services provider in the RNA therapeutics value chain, supporting clients (likely biopharma and academic groups) that require custom RNA molecules and downstream therapeutic development expertise.

The company is operating at very early scale: it is privately held with a headcount of 1–10 employees and no disclosed funding rounds, revenue, or product portfolio details in the available source material. Core technology specifics, proprietary features, products, certifications, partnerships, and management team details are not populated in the data set, and the company's own website (rnatechnologies.com) returned only a loading/verification page with no substantive content during the scrape — a meaningful data gap for due diligence.

The business model is not explicitly disclosed; based on the stated service offering, revenue would presumably derive from fee-for-service contracts for RNA design, synthesis, optimization, and therapeutic development work, but no pricing, contract value, or GTM motion signals are available. Operating geographies, customer segments, and distribution channels are likewise unspecified. In aggregate, the public information supports only a directional view of RNA T&T as a small, early-stage Montréal-based RNA services and therapeutic development firm with limited externally verifiable footprint.

Name

RNA Technologies & Therapeutics (RNA T&T) Inc.

Website

https://rnatechnologies.com

Company type

Private

Founded year

2022

Headcount range

1–10 employees

Short description

RNA Technologies & Therapeutics (RNA T&T) Inc. is a privately-held Montréal-based biotech founded in 2022 that designs, optimizes, and produces RNA and offers RNA-based therapeutic development services to biotech and pharma clients.

Ownership category

akta.pro rank

Product category

RNA Therapeutics Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)

akta.pro secondary industries

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• RNA synthesis services
• RNA therapeutic development
• RNA design optimization
• Biotech contract research
• RNA production services

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D

Core offering

RNA Technologies & Therapeutics (RNA T&T) Inc. designs, optimizes, and produces high-quality RNA molecules and provides RNA-based therapeutic development services. The company serves as a specialized provider of RNA-related contract services for therapeutic applications.

Differentiator

Problem solved

Functional benefit

Products and services

• RNA Design and Optimization Services

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Emerging players

• CureVac: CureVac is a clinical-stage mRNA therapeutics company with internal RNA design, optimization and manufacturing capabilities; it competes indirectly by internalizing work that RNA T&T might otherwise capture as a service provider.
• Arcturus Therapeutics: Arcturus develops mRNA therapeutics with proprietary LNP delivery and in-house RNA manufacturing, representing an emerging competitor with overlapping technology and therapeutic focus.
• Genevant Sciences: Genevant develops lipid nanoparticle delivery technology for RNA therapeutics; it is a relevant adjacent peer in the RNA therapeutics value chain where RNA T&T's clients would also need delivery solutions.

Direct peers

• Bio-Synthesis Inc. Bio-Synthesis is a custom oligonucleotide and gene synthesis provider offering RNA design and production services to research and therapeutic customers, directly overlapping RNA T&T's service scope.
• TriLink BioTechnologies (Maravai LifeSciences): TriLink is a leading CDMO specializing in mRNA, oligonucleotide and nucleic acid manufacturing and is the most direct comparable to RNA T&T's RNA production and therapeutic development services.
• Integrated DNA Technologies (IDT, Danaher): IDT manufactures custom oligonucleotides and RNA reagents at scale and competes for the same research-use and therapeutic RNA synthesis customers as RNA T&T.
• Aldevron (Danaher): Aldevron is a major nucleic acid and protein CDMO serving therapeutic developers globally, directly comparable as an RNA manufacturing and development services provider.

Broad incumbents

• BioNTech: BioNTech is a leading mRNA therapeutics company with extensive proprietary RNA design and large-scale manufacturing; it sets the competitive benchmark and could absorb demand that smaller RNA CDMOs would otherwise serve.
• Eurofins Genomics: Eurofins Genomics offers custom oligonucleotide and gene synthesis services at global scale, representing a broader incumbent competitor for catalog and custom RNA production work.
• Moderna: Moderna is the dominant mRNA therapeutics and vaccine company with end-to-end RNA design and GMP manufacturing capabilities, defining the standard against which specialist RNA service providers are evaluated.

Market position

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/rnatechnologies

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RNA Technologies & Therapeutics (RNA T&T) Inc.